Cary Street Partners Investment Advisory’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
Sell
-20
Closed -$2.64K 616
2025
Q1
$2.64K Buy
+20
New +$2.49K ﹤0.01% 536
2023
Q4
Sell
-1,600
Closed -$83.3K 1836
2023
Q3
$83.3K Hold
1,600
﹤0.01% 753
2023
Q2
$101K Hold
1,600
0.01% 658
2023
Q1
$86.6K Buy
1,600
+20
+1% +$967 0.01% 625
2022
Q4
$83.6K Buy
+1,580
New +$79.2K 0.01% 624

Other funds holding ITCI

Cary Street Partners Investment Advisory's ITCI Position: Q2 2025 in Review

Cary Street Partners Investment Advisory sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 20 shares — an estimated $2.64K sold.

Cary Street Partners Investment Advisory first reported a position in ITCI in Q4 2022 and held it in 5 quarters. The position peaked at $101K in Q2 2023. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

  • Cary Street Partners Investment Advisory reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
  • Cary Street Partners Investment Advisory sold 20 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $2.64K.
  • Cary Street Partners Investment Advisory first reported a position in Intra-Cellular Therapies Inc. in Q4 2022 and held it in 5 quarters.
  • Cary Street Partners Investment Advisory's Intra-Cellular Therapies Inc. position peaked at $101K in Q2 2023.
  • 4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on Cary Street Partners Investment Advisory's 13F filing for Q2 2025, filed 13 Aug 2025.